A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Nevro Reports FDA Approval for Expanded Labeling for Senza® Spinal Cord Stimulation System

Nevro Corp. (NYSE: NVRO) today announced receipt of FDA approval for expanded labeling for its Senza® Spinal Cord Stimulation (SCS) System for the treatment of Non-Surgical Refractory Back Pain (NSRBP).

This approval is specific to Nevro’s proprietary 10 kHz Therapy and differentiates Nevro’s Senza System as the only SCS system with specific labeling to treat NSRBP patients.

“Patients who suffer from intractable back pain without a prior surgery have limited treatment options if they are not a candidate for surgery,” said D. Keith Grossman, Chairman, Chief Executive Officer, and President of Nevro.  “This FDA approval marks another milestone in Nevro’s commitment to expanding access to 10 kHz Therapy for these underserved patients.  Nevro is now the only SCS company with specific, on-label indications for treating both NSRBP and Painful Diabetic Neuropathy patients.”

Mr. Grossman continued, “We would like to thank our lead Principal Investigator team, Dr. Leonardo Kapural, Dr. Jessica Jameson and Dr. Naresh Patel, as well as the rest of our clinical trial investigators and their patients for their study participation and ongoing partnership, without whom this approval would not have been possible.”

The 12-month results for the SENZA-NSRBP RCT were recently presented at the North American Neuromodulation Society (NANS) 25th Annual Meeting on January 15, 2022.¹ SENZA-NSRBP study participants receiving 10 kHz Therapy demonstrated profound improvements in pain relief, function, quality of life, awareness of positive change and reduction in daily opioid use versus Conventional Medical Management (CMM) at 12-months post-implant.  Results also included comparable improvements for patients that crossed over from CMM to 10 kHz after six months.

These data will be used to support continued market penetration and market access initiatives to further expand payer coverage of this procedure.  The company plans to publish these 12-month results, including the six-month crossover patient data, in a peer-reviewed journal.  Study participants will continue to be followed out to 24 months.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy